Clinical Trial Update: Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers [Phase 1]

View source ↗

Summary

ZE74-0282 is the subject of a Phase 1 trial for JAK2 V617F-positive blood cancers, including polycythemia vera and myelofibrosis, and the study is not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• ZE74-0282

Snippet

Sponsor: Eilean Therapeutics | Conditions: Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Status: NOT_YET_RECRUITING